

## Learning Resources

### *General education:*

1. [Fast Facts: Biosimilars eBook : Cornes, P., Bennett, D.J.: Amazon.co.uk: Books](#) – link to FREE Kindle Edition
2. The US Medicines Regulator offers online courses, webinars, and presentations (US-FDA)
  - a. For healthcare professionals: [Webinars, Presentations, and Articles | FDA](#)
  - b. For patients: [Patient Materials | FDA](#)
  - c. For healthcare providers, including sources of data and infographics that are copyright free to reuse: [Health Care Provider Materials | FDA](#)
3. The European Medicines Regulator (EMA)
  - a. Information guide for healthcare professionals: [Biosimilars in the EU - Information guide for healthcare professionals \(europa.eu\)](#)
  - b. And versions in 22 European languages: [Biosimilar medicines: Overview | European Medicines Agency \(europa.eu\)](#)
  - c. Educational video for patients explaining key facts on biosimilars in 8 European languages: [\(8\) EMA Biosimilars - YouTube](#)
  - d. An information guide for patients published by the European Commission in 23 official EU languages: [DocsRoom - European Commission \(europa.eu\)](#)
4. European Specialist Nurses Organisations (ESNO) – Switch Management between Similar Biological Medicines - A Communication and Information Guide for Nurses: [biosimilar-nurses-guideline-final EN.cdr \(esno.org\)](#)
5. The UK Medicines regulator (MHRA) – document produced by the UK National Health Service in collaboration with the MHRA, NICE and industry bodies, entitled ‘What is a biosimilar medicine?’ and provides a detailed and reference guide, including links to information on biosimilar pharmacovigilance and commissioning biosimilar programmes: [NHS England Report Template 1 - long length title](#)
6. Key paper explaining the development and regulatory framework for biosimilars – written by a group of EU regulators: [Biosimilars: what clinicians should know - PubMed \(nih.gov\)](#)
7. A recent key paper on biosimilar [Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective - PubMed \(nih.gov\)](#)
8. Key paper which very clearly explains the concept of extrapolation of indication: [Biosimilars: the science of extrapolation - PubMed \(nih.gov\)](#)
9. Key paper on how biosimilars are made: [Worldwide experience with biosimilar development - PubMed \(nih.gov\)](#)

10. [Biosimilar Interchangeability Regulatory Practical Considerations \(clinicalleader.com\)](https://www.clinicalleader.com)
11. [Interchangeability of Biosimilars: Overcoming the Final Hurdles - PMC \(nih.gov\)](https://pubmed.ncbi.nlm.nih.gov/)
12. [Informing Patients about Biosimilar Medicines: The Role of European Patient Associations - PubMed \(nih.gov\)](https://pubmed.ncbi.nlm.nih.gov/)
13. [Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? - PMC \(nih.gov\)](https://pubmed.ncbi.nlm.nih.gov/)

*For anti-TNF prescribers:*

14. [ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update - PubMed \(nih.gov\)](https://pubmed.ncbi.nlm.nih.gov/)
15. [There Is No Substitute for Effective Education About Biosimilars | Crohn's & Colitis 360 | Oxford Academic \(oup.com\)](https://academic.oup.com/crohn)

*For Rheumatologists:*

16. [Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases | Annals of the Rheumatic Diseases \(bmj.com\)](https://www.bmj.com/)
17. [Effects of Message Framing on Patients' Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch - PubMed \(nih.gov\)](https://pubmed.ncbi.nlm.nih.gov/)